超过10万名1型糖尿病儿童的治疗方案与血糖结局(2013—2022年):儿科糖尿病登记数据纵向分析
该纵向分析纳入8个国家登记库和1个国际登记库中≤18岁、病程>3个月的1型糖尿病儿童数据至2022年达109 494名(国家库)和35 590名(SWEET)。2013—2022年汇总平均HbA1c从8.2%降至7.6%,达到<7%目标比例从19.0%升至38.8%,严重低血糖和糖尿病酮症酸中毒事件率均下降,胰岛素泵和CGM使用比例上升。
要点
- 2013—2022年汇总平均HbA1c从8.2%降至7.6%,达到<7%目标比例从19.0%升至38.8%。
- 严重低血糖事件率从3.0/100人年降至1.7/100人年,糖尿病酮症酸中毒从3.1/100人年降至2.2/100人年。
- 胰岛素泵使用比例从42.9%升至60.2%,CGM从18.7%(2016年)升至81.7%(2022年)。
核心结论
- 2013—2022年血糖结局改善,与糖尿病技术使用增加平行。
- 许多儿童HbA1c高于国际儿科与青少年糖尿病学会(ISPAD)2022年目标。
- 尽管目标HbA1c更低,严重低血糖事件率仍在下降。
- 即使能获得专科诊疗和糖尿病技术的1型糖尿病儿童,仍需糖尿病管理进一步进展以助达到ISPAD血糖目标。
研究设计与样本
- 纵向分析,数据来自8个国家登记库和1个国际登记库(SWEET)。
- 纳入≤18岁、1型糖尿病病程>3个月的儿童。
- 比较2013—2022年数据;分析预定义并由各登记库分别进行。
- 采用ANOVA比较登记库间和年份间均值,采用Joinpoint回归分析时间趋势的显著断点。
- 2022年国家登记库数据109 494名,SWEET数据35 590名。
主要发现
- 2013—2022年汇总平均HbA1c从8.2%(95%CI 8.1-8.3%;66.5 mmol/mol [65.2-67.7])降至7.6%(95%CI 7.5-7.7;59.4 mmol/mol [58.2-60.5])。
- 达到HbA1c<7%(<53 mmol/mol)目标的比例从19.0%升至38.8%(p<0.0001)。
- 严重低血糖汇总事件率从2013年3.0/100人年(95%CI 2.0-4.9)降至2022年1.7/100人年(95%CI 1.0-2.7)。
- 糖尿病酮症酸中毒汇总事件率从2013年3.1/100人年(95%CI 2.0-4.8)降至2022年2.2/100人年(95%CI 1.4-3.4)。
- 胰岛素泵使用比例从2013年42.9%(95%CI 40.4-45.5)升至2022年60.2%(95%CI 57.9-62.6),平均差17.3%(95%CI 13.8-20.7;p<0.0001);CGM使用比例从2016年18.7%(95%CI 9.5-28.0)升至2022年81.7%(95%CI 73.0-90.4),平均差63.0%(95%CI 50.3-75.7;p<0.0001)。
关键数值与推荐
- ISPAD 2022年HbA1c目标:许多儿童HbA1c高于该目标。
- HbA1c目标<7%(<53 mmol/mol)的达标比例从19.0%升至38.8%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in paediatric type 1 diabetes management and increased use of diabetes technology have led to improvements in glycaemia, reduced risk of severe hypoglycaemia, and improved quality of life. Since 1993, progressively lower HbA1c targets have been set. The aim of this study was to perform a longitudinal analysis of HbA1c, treatment regimens, and acute complications between 2013 and 2022 using data from eight national and one international paediatric diabetes registries. METHODS: In this longitudinal analysis, we obtained data from the Australasian Diabetes Data Network, Czech National Childhood Diabetes Register, Danish Registry of Childhood and Adolescent Diabetes, Diabetes Prospective Follow-up Registry, Norwegian Childhood Diabetes Registry, England and Wales' National Paediatric Diabetes Audit, Swedish Childhood Diabetes Registry, T1D Exchange Quality Improvement Collaborative, and the SWEET initiative. All children (aged ≤18 years) with type 1 diabetes with a duration of longer than 3 months were included. Investigators compared data from 2013 to 2022; analyses performed on data were pre-defined and conducted separately by each respective registry. Data on demographics, HbA1c, treatment regimen, and event rates of diabetic ketoacidosis and severe hypoglycaemia were collected. ANOVA was performed to compare means between registries and years. Joinpoint regression analysis was used to study significant breakpoints in temporal trends. FINDINGS: In 2022, data were available for 109 494 children from the national registries and 35 590 from SWEET. Between 2013 and 2022, the aggregated mean HbA1c decreased from 8·2% (95% CI 8·1-8·3%; 66·5 mmol/mol [65·2-67·7]) to 7·6% (7·5-7·7; 59·4mmol/mol [58·2-60·5]), and the proportion of participants who had achieved HbA1c targets of less than 7% (<53 mmol/mol) increased from 19·0% to 38·8% (p<0·0001). In 2013, the aggregate event rate of severe hypoglycaemia rate was 3·0 events per 100 person-years (95% CI 2·0-4·9) compared with 1·7 events per 100 person-years (1·0-2·7) in 2022. In 2013, the aggregate event rate of diabetic ketoacidosis was 3·1 events per 100 person-years (95% CI 2·0-4·8) compared with 2·2 events per 100 person-years (1·4-3·4) in 2022. The proportion of participants with insulin pump use increased from 42·9% (95% CI 40·4-45·5) in 2013 to 60·2% (95% CI 57·9-62·6) in 2022 (mean difference 17·3% [13·8-20·7]; p<0·0001), and the proportion of participants using continuous glucose monitoring (CGM) increased from 18·7% (95% CI 9·5-28·0) in 2016 to 81·7% (73·0-90·4) in 2022 (mean difference 63·0% [50·3-75·7]; p<0·0001). INTERPRETATION: Between 2013 and 2022, glycaemic outcomes have improved, parallel to increased use of diabetes technology. Many children had HbA1c higher than the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 target. Reassuringly, despite targeting lower HbA1c, severe hypoglycaemia event rates are decreasing. Even for children with type 1 diabetes who have access to specialised diabetes care and diabetes technology, further advances in diabetes management are required to assist with achieving ISPAD glycaemic targets. FUNDING: None. TRANSLATIONS: For the Norwegian, German, Czech, Danish and Swedish translations of the abstract see Supplementary Materials section.
引用
- Zimmermann AT, Lanzinger S, Kummernes SJ, et al. Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries. Lancet Diabetes Endocrinol. 2024. PMID: 39622257. doi:10.1016/S2213-8587(24)00279-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。